(Total Views: 542)
Posted On: 05/12/2021 11:46:18 PM
Post# of 149074
SARS-CoV-2 variant proof - to clarify. Lerolimab might not be effective for amino acid substitutions or INDELs in the second extracellular loop of CCR5. Other Mabs may also be SARS-CoV-2 variant proof, such as Narsoplimab, which is in I-SPY and has an FDA action date in July for TMA after HSCT.
translate?
translate?
(0)
(0)Scroll down for more posts ▼
